Graph Therapeutics, a next-generation techbio company developing precision medicines for inflammatory and immune-mediated diseases, has secured a new $5 million investment led by Daphni, the Paris-based venture capital firm. Daphni joins Graph's existing investor syndicate, which includes SquareOne, Merantix Capital, and NAVEC Investment Management. The company has also secured additional non-dilutive funding from the Austrian Research Promotion Agency (FFG) and Austria Wirtschaftsservice (AWS).
With this latest financing, Graph has raised more than $10 million to date, including equity investments and non-dilutive grant funding.
Graph combines perturbation modelling of complex live patient samples, functional and multi-omics profiling, and advanced machine learning through its proprietary "lab-in-the-loop" AI platform to decode immune dysfunction at scale. By generating insights directly from real patient tissue, the company identifies disease mechanisms, novel therapeutic targets, and biomarkers that inform the development of differentiated therapies.
Building on a platform that has been substantially validated and de-risked, Graph is advancing an internal pipeline of precision therapeutics targeting complex inflammatory and immune-mediated diseases.
The company has significantly de-risked and validated its platform through clinically relevant biological models, creating a strong foundation for the development of novel therapeutic programs. The maturity of the platform also opens opportunities for strategic partnerships and out-licensing initiatives, extending the impact of Graph's technology beyond its internal pipeline.
The new capital will support the advancement of Graph's internal drug discovery pipeline across multiple inflammatory and immune-mediated disease indications, while further expanding the company's platform capabilities and strategic partnership opportunities.
Would you like to write the first comment?
Login to post comments